A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. (27th May 2016)

• Record Type: Journal Article
• Authors: Bendell, Johanna C.; Zakari, Ahmed; Lang, Evan; Waterhouse, David; Flora, Douglas; Alguire, Kathryn; McCleod, Michael; Peacock, Nancy; Ruehlman, Peter; Lane, Cassie M.; Earwood, Chris; Shih, Kent
• Is Part Of: Cancer investigation. Volume 34:Number 5(2016)
• Page Start: 213
• Page End: 219
• Publication Date: 2016-05-27
• Subjects: Pancreatic cancer -- Monoclonal antibodies -- Angiogenesis; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.3109/07357907.2016.1174257
• Languages: English
• ISSNs: 0735-7907

Abstract

ABSTRACT: Purpose: To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors. Methods: Patients received bevacizumab 15 mg/kg and pertuzumab 420 mg IV q21 days with octreotide depot 30 mg IM q28 days. Results: Toxicities in 43 patients included diarrhea (63%), fatigue (63%), hypertension (44%), and nausea (44%). Reversible G3 hypertension (26%) and LVEF decline (9%) occurred. 7/43 patients achieved objective response (typical carcinoid, 5; pancreatic NET, 2). Median PFS and OS were 6.5 and 26.4 months, respectively. Discussion: Bevacizumab, pertuzumab, and octreotide depot was well-tolerated with a 16% ORR. Results in the well-differentiated carcinoid tumors are thought provoking.